FDA records identify Ever Fortune.Ai, Co., Ltd. as the applicant behind a cleared radiological triage device. K263109 covers the EFAI NEUROSUITE CTA LVO ASSESSMENT SYSTEM (LVO-CTA-100), which received a substantially equivalent decision on October 30, 2026, following a submission received September 4, 2026. The filing is a Traditional 510(k) reviewed by the Radiology panel, with a Summary statement and no third-party review. The company's documented device line extends to earlier NeuroSuite clearances for CT midline shift and intracranial hemorrhage assessment, each filed under the same regulation and product code. [1][2][5][7][8]

The K263109 clearance and its scope

K263109 names the EFAI NEUROSUITE CTA LVO ASSESSMENT SYSTEM (LVO-CTA-100) as the trade device, with Ever Fortune.Ai, Co., Ltd. as applicant and Joseph Chang as contact. The decision code is SESE, described as Substantially Equivalent, dated October 30, 2026, with a receipt date of September 4, 2026. The submission is a Traditional 510(k) with a Summary statement, no third-party review, and the Radiology advisory committee. The device falls under 21 CFR 892.2080, classification name Radiological Computer-Assisted Triage And Notification Software, product code QAS, Class II. [1][2][5][6]

Innolitics lists the same record with attributes including AI/ML, Software as a Medical Device, and Real-World Evidence, and identifies a related premarket notification K221248 under the same classification name and regulation. FDA.report places K263109 alongside other QAS product-code records from different applicants, including K252366, K253265 and K251610, which indicates the classification grouping rather than any relationship between those firms. [3][4][5]

Earlier NeuroSuite filings

A June 21, 2024 clearance letter for K241923 covers the EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100), addressed to Ever Fortune.AI, Co., Ltd. and to Dr. Ti-Hao Wang as Chief Technology Officer, under 21 CFR 892.2080, product code QAS, Class II. The letter describes assessment of midline shift alongside patient position issues, intracranial hemorrhage, ischemic-stroke and related features, and space-occupying lesions. [7]

A September 4, 2023 substantial equivalence determination for K231025 covers the EFAI NeuroSuite CT ICH Assessment System, again addressed to Ti-Hao Wang as Chief Technology Officer under the same regulation, regulation name and product code. That document describes a retrospective, blinded, multisite validation study of the EFAI ICHCT device on 288 non-contrast head CT studies collected from 23 U.S. clinical sites. These are the performance details of that earlier device, not of K263109. [8]

Applicant identity and record boundaries

The applicant name appears consistently across the K263109 records as Ever Fortune.Ai, Co., Ltd., with a Taichung City, Taiwan filing address and country code TW. That address is the correspondence address on the FDA filing and is not established here as a corporate headquarters. No parent company, brand owner, website or commercial distributor is verified in these records, so the applicant is treated as the legal submitter only. [1][5][6]

Arca reports that as of November 19, 2026, K263109 is an FDA 510(k) held by Ever Fortune.Ai, Co., Ltd., substantially equivalent on October 30, 2026 after 56 days, with no recalls tied to it in FDA's recall database. That review-time figure and recall statement come from Arca's indexing of public records, not from the FDA decision documents themselves. [9]

What the record collection shows

The linked filing collection for this company contains one 510(k) record, K263109, with one SESE decision, and the record sample likewise contains that single entry. These counts describe the retrieved filings as of the snapshot date and are not a measure of total company sales, total portfolio or safety performance. The earlier K241923 and K231025 clearances appear in the numbered sources as separate FDA documents and are not part of that linked collection count. [1][7][8]